Could a common drug ease sickle cell pain for african children?

NCT ID NCT01966731

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether hydroxyurea, a drug already used for sickle cell disease in other parts of the world, is safe and effective for children with sickle cell anemia in Africa. Children aged 1 to 10 years receive daily doses of hydroxyurea, with careful monitoring for side effects and improvements in blood counts and pain crises. The goal is to gather evidence that could make this treatment more accessible across the continent.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Hydroxyurea
What this could lead to
If successful, this could make hydroxyurea widely available for children with sickle cell anemia in Africa, reducing pain episodes and hospital visits.
What could go wrong
This is an early-phase study, so the full benefits and risks are not yet known. Hydroxyurea can lower blood cell counts, requiring careful monitoring.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Centre Hospitalier Monkole

    Kinshasa, Democratic Republic of the Congo

  • Hospital Pediátrico David Bernardino

    Luanda, Angola

  • KEMRI/Wellcome Trust Research

    Kilifi, Kenya

  • Ministry of Health Mbale Regional Hospital

    Mbale, Uganda

More trials for these conditions

Other studies related to the condition(s) this trial covers.